JP2024544075A - ブルーリ潰瘍におけるマイコバクテリウム・ウルセランスの局所治療のための製剤及び方法 - Google Patents
ブルーリ潰瘍におけるマイコバクテリウム・ウルセランスの局所治療のための製剤及び方法 Download PDFInfo
- Publication number
- JP2024544075A JP2024544075A JP2024532467A JP2024532467A JP2024544075A JP 2024544075 A JP2024544075 A JP 2024544075A JP 2024532467 A JP2024532467 A JP 2024532467A JP 2024532467 A JP2024532467 A JP 2024532467A JP 2024544075 A JP2024544075 A JP 2024544075A
- Authority
- JP
- Japan
- Prior art keywords
- clofazimine
- pharmaceutical composition
- topical pharmaceutical
- composition according
- suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284426P | 2021-11-30 | 2021-11-30 | |
| US63/284,426 | 2021-11-30 | ||
| PCT/US2022/080537 WO2023102363A1 (en) | 2021-11-30 | 2022-11-29 | Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024544075A true JP2024544075A (ja) | 2024-11-27 |
| JP2024544075A5 JP2024544075A5 (cg-RX-API-DMAC10.html) | 2025-12-05 |
Family
ID=86613091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024532467A Pending JP2024544075A (ja) | 2021-11-30 | 2022-11-29 | ブルーリ潰瘍におけるマイコバクテリウム・ウルセランスの局所治療のための製剤及び方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240390366A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024544075A (cg-RX-API-DMAC10.html) |
| CN (1) | CN118317771A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022399569A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023102363A1 (cg-RX-API-DMAC10.html) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5610198A (en) * | 1994-03-18 | 1997-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases |
| WO2007085057A1 (en) * | 2006-01-25 | 2007-08-02 | The Council Of The Queensland Institute Of Medical Research | A medical protocol |
| GB0709513D0 (en) * | 2007-05-17 | 2007-06-27 | Helperby Therapeutics Ltd | Topical formulations |
| US9018216B2 (en) * | 2012-07-18 | 2015-04-28 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof |
| WO2016179231A1 (en) * | 2015-05-04 | 2016-11-10 | Board Of Trustees Of Michigan State University | Compositions and methods for inhibiting bacterial growth |
| US11572588B2 (en) * | 2017-07-19 | 2023-02-07 | The Regents Of The University Of Colorado, A Body Corporate | Methods of evaluating treatment efficacy and/or treatment duration in mycobacterial diseases |
| WO2021184339A1 (en) * | 2020-03-20 | 2021-09-23 | Merck Sharp & Dohme Corp. | Oxazolidinone compound and methods of use thereof as an antibacterial agent |
| CA3180160A1 (en) * | 2020-04-17 | 2021-10-21 | Shenzhen Pharmacin Co., Ltd | Pharmaceutical compositions |
| JP7893751B2 (ja) * | 2020-05-01 | 2026-07-22 | マンカインド コーポレイション | ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法 |
-
2022
- 2022-11-29 WO PCT/US2022/080537 patent/WO2023102363A1/en not_active Ceased
- 2022-11-29 CN CN202280079174.4A patent/CN118317771A/zh active Pending
- 2022-11-29 AU AU2022399569A patent/AU2022399569A1/en active Pending
- 2022-11-29 US US18/714,456 patent/US20240390366A1/en active Pending
- 2022-11-29 JP JP2024532467A patent/JP2024544075A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022399569A1 (en) | 2024-06-06 |
| US20240390366A1 (en) | 2024-11-28 |
| WO2023102363A1 (en) | 2023-06-08 |
| CN118317771A (zh) | 2024-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3240330B2 (ja) | コラン酸の塩を含有する医薬調合剤および化粧品調合剤 | |
| US20050255048A1 (en) | Sprayable formulations for the treatment of acute inflammatory skin conditions | |
| HUE027184T2 (en) | Combination of azelastine and cyclesonide | |
| EP1477166A1 (de) | Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis | |
| JP2020505469A (ja) | 治療用アプレミラスト局所組成物 | |
| JP2001504091A (ja) | 病原性生物による鼻咽腔のコロニー形成に関連する細菌感染の治療のための薬剤の製造のためのミュピロシンの使用 | |
| JP2007505927A (ja) | 薬物送達システム | |
| JP2022512208A5 (cg-RX-API-DMAC10.html) | ||
| WO2007126865A2 (en) | Leukotriene antagonists via nasal drug delivery | |
| JP2007509952A (ja) | ロテプレドノールエタボネートおよびトブラマイシンの局所眼科用懸濁液 | |
| US20230082254A1 (en) | Topical therapeutic formulations | |
| AU2008331500B2 (en) | Intravesical compositions with valrubicin for the treatment of bladder cancer | |
| US8263567B2 (en) | Treatment of hyperproliferative conditions of body surfaces | |
| WO2023102363A1 (en) | Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers | |
| HK40111713A (en) | Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers | |
| WO2019152560A1 (en) | Compositions and methods for topical treatment of dermal and ocular conditions | |
| US20230149352A1 (en) | Uses of apremilast | |
| WO2009007827A2 (en) | Novel diclofenac esters and uses thereof | |
| JP2024544075A5 (cg-RX-API-DMAC10.html) | ||
| JP7512365B2 (ja) | 油性外用液 | |
| HK40129829A (en) | Treatment of uremic pruritus | |
| AU2002320964A1 (en) | Treatment of hyperproliferative conditions of body surfaces | |
| WO2024159048A1 (en) | Treatment of uremic pruritus | |
| WO2005053672A1 (ja) | シロミラストまたはその塩を有効成分とする掻痒治療剤 | |
| HK40129381A (en) | Treatment of chronic pruritic dermatoses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240531 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251127 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251127 |